Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 4;14(1):15390.
doi: 10.1038/s41598-024-65972-8.

Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients

Inès Saizonou #  1 , Isabelle Lascombe #  2 , Franck Monnien  1 , Isabelle Bedgedjian  1 , François Kleinclauss  3 , Marie-Paule Algros  1 , Sylvie Fauconnet  4   5   6
Affiliations

Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients

Inès Saizonou et al. Sci Rep. .

Abstract

Non-muscle invasive bladder cancers (NMIBC) pTa-pT1 are depicted by a high risk of recurrence and/or progression with an unpredictable clinical evolution. Our aim was to identify, from the original resection specimen, tumors that will progress to better manage patients. We previously showed that A-FABP (Adipocyte- Fatty Acid Binding Protein) loss predicted NMIBC progression. Here we determined by immunohistochemistry the prognostic value of E-FABP (Epidermal-Fatty Acid Binding Protein) expression in 210 tumors (80 pTa, 75 pT1, 55 pT2-T4). Thus, E-FABP low expression was correlated with a high grade/stage, the presence of metastatic lymph nodes, and visceral metastases (p < 0.001). Unlike A-FABP in NMIBC, E-FABP low expression was not associated with RFS or PFS in Kaplan-Meier analysis. But patients of the overall cohort with a high E-FABP expression had a longer mOS (53.8 months vs. 29.3 months, p = 0.029). The immunohistochemical analysis on the same NMIBC tissue sections revealed that when A-FABP is absent, a high E-FABP expression is detected. E-FABP could compensate A-FABP loss. Interestingly, patients, whose original tumor presents both low E-FABP and negative A-FABP, had the worse survival, those maintaining the expression of both markers had better survival. To conclude, the combined evaluation of A- and E-FABP expression allowed to stratify patients with urothelial carcinoma for optimizing treatment and follow-up.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Immunohistochemical analysis of E-FABP expression in brain (negative control) (a), psoriatic skin (positive control) (b), normal urothelium (c), pTa papillary UC (d), pT1 (e) and pT2 tumors (f). Magnification X200.
Figure 2
Figure 2
Kaplan–Meier curves for high and low E-FABP expression in relation to RFS and PFS in patients with pTa (a, b) or pT1 tumor (c, d).
Figure 3
Figure 3
Kaplan–Meier plots comparing overall survival for patients stratified by E-FABP expression level in the whole cohort (a), in patients with pTa (b) or pT1 (c) UC.
Figure 4
Figure 4
Kaplan–Meier curves comparing overall survival for patients stratified according to both E- and A-FABP expression status in the whole cohort (a), in patients with pTa (b) or pT1 (c) UC.
See this image and copyright information in PMC

References

    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L. Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology. 2008;53:621–633. doi: 10.1111/j.1365-2559.2008.03025.x. - DOI - PubMed
    1. Gospodarowicz MK, Mason M. Urological Tumors. In: Brierley DJ, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumors. 8. Wiley; 2017. pp. 204–207.
    1. Kurth KH, et al. Treatment of superficial bladder tumors: Achievements and needs. The EORTC Genitourinary Group. Eur Urol. 2000;37:1–9. - PubMed
    1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239–249. doi: 10.1016/S0140-6736(09)60491-8. - DOI - PubMed